Karl K. Alornyo

Combination Therapy of Alpha-Lipoic Acid, Gliclazide and Ramipril Protects Against Development of Diabetic Cardiomyopathy via Inhibition of TGF-β/Smad Pathway

V. Boima, George J. Dugbartey, G. J. Dugbartey, 2022, Frontiers in Pharmacology.

Alpha-lipoic acid treatment improves adverse cardiac remodelling in the diabetic heart - The role of cardiac hydrogen sulfide-synthesizing enzymes.

George J. Dugbartey, G. J. Dugbartey, Quinsker L. Wonje, 2022, Biochemical pharmacology.

Targeting hepatic sulfane sulfur/hydrogen sulfide signaling pathway with α-lipoic acid to prevent diabetes-induced liver injury via upregulating hepatic CSE/3-MST expression

S. Adjei, George J. Dugbartey, G. J. Dugbartey, 2022, Diabetology & Metabolic Syndrome.

Application of carbon monoxide in kidney and heart transplantation: A novel pharmacological strategy for a broader use of suboptimal renal and cardiac grafts.

A. Şener, P. Luke, George J. Dugbartey, 2021, Pharmacological research.

Supplementation of conventional anti-diabetic therapy with alpha-lipoic acid prevents early development and progression of diabetic nephropathy.

S. Adjei, Benoit Banga N'guessan, George J. Dugbartey, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Renal consequences of the novel coronavirus disease 2019 (COVID-19) and hydrogen sulfide as a potential therapy

A. Şener, V. Boima, S. Antwi, 2022, Nitric Oxide.

Activation of renal CSE/H2S pathway by alpha-lipoic acid protects against histological and functional changes in the diabetic kidney.

George J. Dugbartey, G. J. Dugbartey, Karl K. Alornyo, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.